UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

 Quarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended: September 30, 2024

 

or

 

 Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from ______ to_______

 

Commission File No. 001-35927

 

AIR INDUSTRIES GROUP

(Exact name of registrant as specified in its charter)

 

Nevada   80-0948413
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

1460 Fifth Avenue, Bay Shore, New York 11706

(Address of principal executive offices)

 

(631) 968-5000

(Registrant’s telephone number, including area code)

 

Securities Registered pursuant to Section 12(b) of the Act

 

Title of Each Class   Trading Symbol(s)   Name of each Exchange on which Registered
Common Stock   AIRI   NYSE-American

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒  No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large Accelerated Filer  ☐ Non-Accelerated Filer ☒
Accelerated Filer  ☐ Smaller Reporting Company
  Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No 

 

There were 3,358,119 shares of the registrant’s common stock outstanding as of November 12, 2024.

 

 

  

 

 

 

INDEX

 

      Page No.
PART I. FINANCIAL INFORMATION   1
     
Item 1. Financial Statements   2
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   22
     
Item 4. Controls and Procedures   29
     
PART II.  OTHER INFORMATION   30
       
Item 1A. Risk Factors   30
       
Item 6. Exhibits   30
     
SIGNATURES   31

 

i

 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, or Exchange Act. Forward-looking statements are predictive in nature and can be identified by the fact that they do not relate strictly to historical or current facts and generally include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates” and similar expressions. Certain of the matters discussed herein concerning, among other items, our operations, cash flows, financial position and economic performance including, in particular, future sales, product demand, competition and the effect of economic conditions, include forward-looking statements.

 

These statements and other projections contained herein expressing opinions about future outcomes and non-historical information, are subject to uncertainties and, therefore, there is no assurance that the outcomes expressed in these statements will be achieved. Investors are cautioned that forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from the expectations expressed in forward-looking statements contained herein. Given these uncertainties, you should not place any reliance on these forward-looking statements which speak only as of the date hereof. Factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, those discussed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and elsewhere in this report and the risks discussed in our other filings with the Securities Exchange Commission.

 

We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required under the securities laws of the United States.

 

ii

 

 

PART I

 

FINANCIAL INFORMATION

 

    Page No.
Item 1. Financial statements   2
     
Condensed Consolidated Financial Statements:    
     
Condensed Consolidated Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023   2
     
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (unaudited)   3
     
Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2024 and 2023 (unaudited)   4
     
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 (unaudited) 5
     
Notes to Condensed Consolidated Financial Statements (unaudited)   7

 

1

 

 

ITEM 1. FINANCIAL STATEMENTS

 

AIR INDUSTRIES GROUP

Condensed Consolidated Balance Sheets

 

   September 30,   December 31, 
   2024   2023 
   (unaudited)     
ASSETS        
Current Assets        
Cash  $186,000   $346,000 
Accounts Receivable, Net of Allowance for Credit Losses of $237,000 and $344,000   7,259,000    7,892,000 
Inventory   30,509,000    29,851,000 
Prepaid Expenses and Other Current Assets   314,000    297,000 
Contract Costs Receivable   296,000    296,000 
Prepaid Taxes   55,000    37,000 
Total Current Assets   38,619,000    38,719,000 
           
Property and Equipment, Net   8,521,000    8,048,000 
Finance Lease Right-Of-Use-Assets   1,161,000    970,000 
Operating Lease Right-Of-Use-Assets   1,366,000    1,866,000 
Deferred Financing Costs, Net, Deposits and Other Assets   698,000    1,112,000 
           
TOTAL ASSETS  $50,365,000   $50,715,000 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current Liabilities          
Debt  $17,066,000   $16,036,000 
Accounts Payable and Accrued Expenses   7,101,000    6,091,000 
Operating Lease Liabilities   890,000    880,000 
Deferred Gain on Sale - Leaseback   38,000    38,000 
Customer Deposits   1,717,000    3,557,000 
Total Current Liabilities   26,812,000    26,602,000 
           
Long Term Liabilities          
Debt   1,748,000    1,112,000 
Subordinated Notes - Related Party   6,162,000    6,162,000 
Operating Lease Liabilities   925,000    1,582,000 
Deferred Gain on Sale - Leaseback   38,000    67,000 
TOTAL LIABILITIES   35,685,000    35,525,000 
           
Commitments and Contingencies (see Note 8)   
 
    
 
 
           
Stockholders’ Equity          
Preferred Stock - par value $.001 - Authorized 3,000,000 shares, 0 shares outstanding, at both September 30, 2024 and December 31, 2023.   
-
    
-
 
Common Stock - Par Value $.001 - Authorized 6,000,000 shares, 3,350,791 and 3,303,045 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively   3,000    3,000 
Additional Paid-In Capital   83,230,000    82,928,000 
Accumulated Deficit   (68,553,000)   (67,741,000)
TOTAL STOCKHOLDERS’ EQUITY   14,680,000    15,190,000 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $50,365,000   $50,715,000 

 

See Notes to Condensed Consolidated Financial Statements.

 

2

 

 

AIR INDUSTRIES GROUP
Condensed Consolidated Statements of Operations
(Unaudited)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2024   2023   2024   2023 
                 
Net Sales  $12,555,000   $12,293,000   $40,188,000   $38,047,000 
                     
Cost of Sales   10,614,000    11,065,000    33,697,000    32,769,000 
                     
Gross Profit   1,941,000    1,228,000    6,491,000    5,278,000 
                     
Operating Expenses   1,874,000    2,024,000    5,931,000    6,160,000 
                     
Income (Loss) from Operations   67,000    (796,000)   560,000    (882,000)
                     
Interest Expense   (364,000)   (398,000)   (1,064,000)   (1,118,000)
                     
Interest Expense - Related Parties   (118,000)   (118,000)   (354,000)   (354,000)
                     
Other Income, Net   11,000    13,000    46,000    42,000 
                     
Loss before Income Taxes   (404,000)   (1,299,000)   (812,000)   (2,312,000)
                     
Provision for Income Taxes   
-
    
-
    
-
    
-
 
                     
Net Loss  $(404,000)  $(1,299,000)  $(812,000)  $(2,312,000)
                     
Loss per share - Basic  $(0.12)  $(0.40)  $(0.24)  $(0.71)
                     
Loss per share - Diluted  $(0.12)  $(0.40)  $(0.24)  $(0.71)
                     
Weighted Average Shares Outstanding - Basic   3,338,705    3,286,682    3,326,245    3,270,399 
Weighted Average Shares Outstanding - Diluted   3,338,705    3,286,682    3,326,245    3,270,399 

 

See Notes to Condensed Consolidated Financial Statements.

 

3

 

 

AIR INDUSTRIES GROUP

Condensed Consolidated Statements of Changes in Stockholders’ Equity

For the Three and Nine Months Ended September 30, 2024 and 2023

(Unaudited)

 

           Additional       Total 
   Common Stock   Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Capital   Deficit   Equity 
Balance January 1, 2024   3,303,045   $3,000   $82,928,000   $(67,741,000)  $15,190,000 
Common Stock issued to directors   12,323    
-
    38,000    
-
    38,000 
Stock-Based Compensation   -    
-
    24,000    
-
    24,000 
Net Loss   -    
-
    
-
    (706,000)   (706,000)
Balance, March 31, 2024   3,315,368   $3,000   $82,990,000   $(68,447,000)  $14,546,000 
                          
Common Stock issued to directors   7,942    
-
    38,000    
-
    38,000 
Stock-Based Compensation   -    
-
    12,000    
-
    12,000 
Exercise of Stock Options   1,475    
-
    
-
    
-
    
-
 
Net Income   -    
-
    
-
    298,000    298,000 
Balance, June 30, 2024   3,324,785   $3,000   $83,040,000   $(68,149,000)  $14,894,000 
                          
Common Stock issued to directors   12,252         40,000         40,000 
Stock-Based Compensation             150,000         150,000 
Exercise of Stock Options   13,754                   - 
Net Loss                  (404,000)   (404,000)
Balance, September 30, 2024   3,350,791   $3,000   $83,230,000   $(68,553,000)  $14,680,000 
                          
Balance, January 1, 2023   3,247,930   $3,000   $82,446,000   $(65,610,000)   16,839,000 
Common Stock issued to directors   11,430    
-
    54,000    
-
    54,000 
Stock-Based Compensation   -    
-
    45,000    
-
    45,000 
Net Loss   -    
-
    
-
    (618,000)   (618,000)
Balance, March 31, 2023   3,259,360   $3,000   $82,545,000   $(66,228,000)  $16,320,000 
                          
Common Stock issued to directors   15,230    
-
    54,000    
-
    54,000 
Stock-Based Compensation   -    
-
    187,000    
-
    187,000 
Net Loss   -    
-
    
-
    (395,000)   (395,000)
Balance, June 30, 2023   3,274,590   $3,000   $82,786,000   $(66,623,000)  $16,166,000 
                          
Common Stock issued to directors   15,230    
-
    54,000    
-
    54,000 
Stock-Based Compensation   -    
-
    28,000    
-
    28,000 
Net Loss   -    
-
    
-
    (1,299,000)   (1,299,000)
Balance, September 30, 2023   3,289,820   $3,000   $82,868,000   $(67,922,000)  $14,949,000 

 

See Notes to Condensed Consolidated Financial Statements.

 

4

 

 

AIR INDUSTRIES GROUP

Condensed Consolidated Statements of Cash Flows

For the Nine Months Ended September 30,
(Unaudited)

 

   2024   2023 
         
CASH FLOWS FROM OPERATING ACTIVITIES        
Net Loss  $(812,000)  $(2,312,000)
Adjustments to reconcile net loss to net cash provided by operating activities          
Depreciation of property and equipment   1,533,000    1,807,000 
Stock-based compensation   302,000    422,000 
Amortization of Finance Lease Right-of-Use Assets   128,000    46,000 
Amortization of Operating Lease Right-of-Use Assets   500,000    449,000 
Deferred gain on sale - leaseback   (29,000)   (29,000)
Gain on sale of equipment   (7,000)   
-
 
Changes in allowance for credit losses   (106,000)   38,000 
Amortization of deferred financing costs   51,000    51,000 
Changes in Operating Assets and Liabilities          
(Increase) Decrease in Operating Assets:          
Accounts receivable   739,000    4,224,000 
Inventory   (658,000)   473,000 
Prepaid expenses and other current assets   (17,000)   72,000 
Prepaid taxes   (18,000)   - 
Deposits and other assets   379,000    (20,000)
Increase (Decrease) in Operating Liabilities:          
Accounts payable and accrued expenses   1,010,000    (251,000)
Operating lease liabilities   (647,000)   (572,000)
Customer deposits   (1,840,000)   2,695,000 
NET CASH PROVIDED BY OPERATING ACTIVITIES   508,000    7,093,000 
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of property and equipment   (1,500,000)   (1,867,000)
Proceeds from sale of equipment   7,000    
-
 
NET CASH USED IN INVESTING ACTIVITIES   (1,493,000)   (1,867,000)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Note payable - revolver - net - Current Credit Facility   633,000    (4,908,000)
Proceeds from term loan - Current Credit Facility   1,006,000    740,000 
Proceeds from term loan - CT Green Bank   
-
    393,000 
Payments of term loan - Current Credit Facility   (665,000)   (876,000)
Payments of deferred financing costs   
-
    (25,000)
Payments of finance lease obligations   (143,000)   (84,000)
Payments of loan payable - financed asset   (6,000)   (7,000)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES   825,000    (4,767,000)
           
NET (DECREASE) INCREASE IN CASH   (160,000)   459,000 
CASH AT BEGINNING OF PERIOD   346,000    281,000 
CASH AT END OF PERIOD  $186,000   $740,000 

 

See Notes to Condensed Consolidated Financial Statements.

 

5

 

 

AIR INDUSTRIES GROUP

Condensed Consolidated Statements of Cash Flows For the Nine Months Ended September 30, (Continued)
(Unaudited)

 

   2024   2023 
         
Supplemental cash flow information        
Cash paid during the nine month period for interest  $1,387,000   $1,472,000 
           
Supplemental disclosure of non-cash investing and financing activities          
Acquisition of financed lease asset  $319,000   $679,000 
Financing from Solar Credit Facility directly to contractor  $506,000   $
-
 

 

See Notes to Condensed Consolidated Financial Statements.

 

6

 

 

AIR INDUSTRIES GROUP

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Note 1. ORGANIZATION AND BASIS OF PRESENTATION

 

Organization

 

Air Industries Group is a Nevada corporation (“AIRI”). The accompanying condensed consolidated financial statements presented are those of AIRI, and its wholly-owned subsidiaries; Air Industries Machining Corp. (“AIM”), Nassau Tool Works, Inc. (“NTW”), and the Sterling Engineering Corporation (“Sterling”) (together, the “Company”).

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on April 15, 2024, from which the accompanying condensed consolidated balance sheet dated December 31, 2023 was derived.

 

Going Concern and Management’s Plan

 

At each reporting period, management evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. The Company is required to make certain additional disclosures if management concludes substantial doubt exists about the Company’s ability to continue as a going concern provided that such doubt is not alleviated by the Company’s plans or when the Company’s plans do not alleviate substantial doubt about its ability to continue as a going concern. This evaluation entails analyzing prospective operating budgets and forecasts for expectations regarding cash needs and comparing those needs to the current cash balance and expectations regarding cash to be generated over the following year.

 

For the nine months ended September 30, 2024, the Company generated $508,000 of cash from operating activities, compared to $7,093,000 for the same period in 2023. The debt under the Current Credit Facility as of September 30, 2024, amounted to approximately $16,838,000, reflecting an increase of $989,000 since December 31, 2023. The Company received a Waiver and entered into the Seventh Amendment to the Loan and Security Agreement under the Current Credit Facility on May 31, 2024. As of September 30, 2024, the Company is in compliance with the terms of the Current Credit Facility. See Note 5. Debt for the terms of the Seventh Amendment. As of September 30, 2024, total outstanding debt was $24,976,000, with the nature and terms of such debt further discussed in Note 5. Debt.

 

Management’s plans expect net sales to increase in fiscal 2024 as compared to fiscal 2023 with increasing amounts into fiscal 2025 and thereafter. The Company believes that these plans are supported by the Company’s existing backlog, which increased from $98.1 million as of December 31, 2023 to $105.2 million at September 30, 2024. Further, it anticipates receiving additional funded orders during 2024 and 2025 pursuant to Long-Term Agreements (“LTA”) agreements from its key customers as well as from new customers. With this visibility, the Company expects that it will generate sufficient cash flow to make required principal payments (exclusive of any potential debt payment acceleration should the lender under the Current Credit Facility choose to accelerate it) pursuant to the Current Credit Facility of approximately $814,000 over the next twelve months.

 

7

 

 

The Company obtained a waiver of the requirement to meet the Fixed Coverage Charge Ratio at March 31, 2024, and met its covenants as of both June 30 and September 30, 2024. Nevertheless, the Company may fail to achieve the required covenants in the future. Therefore, the Company classified the term loan that expires on December 30, 2025 in the amount of $5,401,000 and $5,045,000 as current as of September 30, 2024 and December 31, 2023, respectively, in accordance with the guidance in Accounting Standards Codification (“ASC”) 470-10-45, “Debt – Other Presentation Matters”, related to the classification of callable debt. The Company is required to maintain a collection account with its lender into which substantially all cash receipts are remitted. If it were to default under the Current Credit Facility, the Company’s lender could choose to increase the rate of interest or refuse to make loans under the revolving portion of the Current Credit Facility and keep the funds remitted to the collection account. If the lender were to raise the rate of interest, it would adversely impact the Company’s operating results. If the lender were to cease making new loans under the revolving facility, the Company would lack the funds to continue operations. The rights granted to the lender under the Current Credit Facility combined with the reasonable possibility that the Company might fail to meet covenants in the future raise substantial doubt about its ability to continue as a going concern for the one year commencing as of the date of filing these interim condensed consolidated financial statements.

 

The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern. 

 

Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Accounts Receivable

 

Accounts receivable are carried at the original invoice amount less an estimate made for credit losses based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for credit losses by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, current economic conditions and other relevant factors, including specific reserves for certain accounts. Accounts receivable are written off when deemed uncollectible.  Bad debt expenses are recorded in operating expenses on the condensed consolidated statements of operations.

 

The activity for the allowance for credit losses during the nine months ended September 30, 2024 and 2023 is set forth in the table below

 

   Balance at       Deductions   Balance at 
   Beginning of   Charged to   from the   End of 
   Period   Expenses   Allowance   Period 
Nine Months ended September 30, 2024 Allowance for Credit Losses  $344,000   $26,000   $(133,000)  $237,000 
Nine Months ended September 30, 2023 Allowance for Credit Losses  $281,000   $

67,000

   $
-
  $348,000 

 

Inventory Valuation

 

The Company values inventory at the lower of cost or an estimated net realizable value. The Company periodically evaluates inventory items not secured by backlog and establishes write-downs to estimated net realizable value for excess quantities, slow-moving goods, obsolescence and for other impairments of value.

 

Inventories consist of the following at:

 

   September 30,   December 31, 
   2024   2023 
Raw Materials  $6,497,000   $4,968,000 
Work In Progress   13,514,000    12,798,000 
Semi-Finished Goods   9,288,000    10,296,000 
Final-Finished Goods   1,210,000    1,789,000 
Total Inventory  $30,509,000   $29,851,000 
           

 

8

 

 

Credit and Concentration Risks

 

A large percentage of the Company’s revenues are derived directly from large aerospace and defense prime contractors for which the ultimate end-user is the U.S. Government, other governments, or commercial airlines.

 

The composition of customers that exceeded 10% of net sales for the three months ended September 30, 2024 and 2023 are shown below:

 

  Percentage of Net Sales 
Customer  2024   2023 
RTX (a)   27.8%   20.1%
Lockheed   23.9%   31.9%
Northrop   18.3%   
-
 
Boeing   
-
    18.0%

 

(a)RTX includes Collins Landing Systems and Collins Aerostructures

 

The composition of customers that exceeded 10% of net sales for the nine months ended September 30, 2024 and 2023 are shown below:

 

  Percentage of Net Sales 
Customer  2024   2023 
RTX (a)   27.0%   26.6%
Lockheed   25.1%   24.7%
Northrop   19.9%   2.6%
Ruag   1.5%   10.9%
Boeing   0.3%   10.0%

 

(a)RTX includes Collins Landing Systems and Collins Aerostructures

 

The composition of customers that exceed 10% of accounts receivable at September 30, 2024 and December 31, 2023 are shown below:

 

  Percentage of Net Receivables 
   September 30,   December 31, 
Customer  2024   2023 
RTX (a)   43.5%   45.5%
Lockheed   13.9%   3.7%
Northrop   13.7%   8.2%
Boeing   
-
    16.0%

 

(a)RTX includes Collins Landing Systems and Collins Aerostructures

 

Disaggregation of Revenue

  

The following table summarizes revenue from contracts with customers for the three and nine month periods ending September 30, 2024 and 2023:

 

   Three Months Ended   Nine Months Ended 
Product  September 30,
2024
   September 30,
2023
   September 30,
2024
   September 30,
2023
 
Military  $7,968,000   $10,144,000   $28,272,000   $31,513,000 
Commercial   4,587,000    2,149,000    11,916,000    6,534,000 
Total  $12,555,000   $12,293,000   $40,188,000   $38,047,000 

 

9

 

 

Cash

 

During the period ended September 30, 2024, the Company had occasionally maintained balances in its bank accounts that were in excess of the FDIC limit. The Company has not experienced any losses on these accounts.

 

Major Suppliers

 

The Company utilizes sole-source suppliers to supply raw materials or other parts used in production. These suppliers are its only source for such parts and, therefore, in the event any of them were to go out of business or be unable to provide parts for any reason, the Company’s business would be severely harmed.

 

Customer Deposits

 

The Company receives advance payments on certain contracts with the remainder of the contract balance due upon shipment of the final product once the customer inspects and approves the product for shipment. At that time, the entire amount will be recognized as revenue and the deposit will be applied to the customer’s invoice.

 

At September 30, 2024 and December 31, 2023, customer deposits were $1,717,000 and $3,557,000 respectively. The Company recognized revenue of $544,000 and $1,840,000 during the three and nine months ended September 30, 2024, respectively, that was included in the customer deposits balance as of December 31, 2023. The Company recognized revenue of $147,000 and $461,000 during the three and nine months ended September 30, 2023, respectively, that was included in the customer deposits balance as of December 31, 2022.

 

Backlog

 

Backlog represents the value of orders received pursuant to our Long-Term Agreements (“LTA”) or spot orders pursuant to a purchase order. As of September 30, 2024, backlog relating to remaining performance obligations on contracts was approximately $105.2 million. The Company estimates that a substantial portion of this backlog will be recognized as net sales during the next twenty-four-months, with the rest thereafter. This expectation assumes that raw material supplies and outsourced processing is completed and delivered on time and that the Company’s customers will accept delivery as scheduled. The Company anticipates that sales during the aforementioned periods will also include sales from expected new orders that are not included in backlog.

 

Contract Costs Receivable

 

Contract costs receivable represent costs to be reimbursed from a terminated contract. The Company expects to collect the receivable in the next twelve months. Contract costs receivable totals $296,000 at both September 30, 2024 and December 31, 2023.

 

Earnings (Loss) per share

 

Basic earnings (loss) per share (“EPS”) is computed by dividing the net income (loss) applicable to common stockholders by the weighted-average number of shares of common stock outstanding for the period.

 

For purposes of calculating diluted earnings (loss) per common share, the numerator includes net income (loss) plus interest on convertible notes payable assumed converted as of the first day of the period. The denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options, restricted units and warrants using the treasury stock method and convertible notes payable using the if-converted method.

 

10

 

 

The following securities have been excluded from the calculation as the exercise price was greater than the average market price of the common shares:

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30,   September 30,   September 30, 
   2024   2023   2024   2023 
 Stock Options   236,753    462,870    236,753    462,870 
    236,753    462,870    236,753    462,870 

 

The following securities have been excluded from the calculation because the effect of including these potential shares was anti-dilutive due to the net loss incurred during these periods:

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30,   September 30,   September 30, 
   2024   2023   2024   2023 
 Stock Options   154,250    
-
    154,250    
-
 
 Restricted Stock Units   282,628    
-
    282,628    
-
 
 Convertible notes payable   405,800    405,800    405,800    405,800 
    842,678    405,800    842,678    405,800 

 

Stock-Based Compensation

 

The Company accounts for stock-based compensation in accordance with FASB ASC 718, “Compensation – Stock Compensation.” Under the fair value recognition provision of the ASC, stock-based compensation cost is estimated at the grant date based on the fair value of the award. The Company estimates the fair value of stock options and warrants granted using the Black-Scholes-Merton option pricing model and stock grants at their closing reported market value. Stock-based compensation expense for employees amounted to $150,000 and $28,000 for the three months ended September 30, 2024 and 2023, respectively, and $186,000 and $260,000 for the nine months ended September 30, 2024 and 2023, respectively. Stock compensation expense for directors amounted to $40,000 and $54,000 for the three months ended September 30, 2024 and 2023, respectively, and $116,000 and $162,000 for the nine months ended September 30, 2024 and 2023, respectively. Stock compensation expenses for employees and directors were included in operating expenses in the accompanying condensed consolidated statements of operations. 

 

Recently Issued Accounting Pronouncements

 

In November 2023, Financial Accounting Standards Board (“FASB) issued Accounting Standards Updated (“ASU”) 2023-07 - Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities with a single reportable segment to provide all the disclosures required by this standard and all existing segment disclosures in Topic 280 on an interim and annual basis, including new requirements to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within the reported measure(s) of a segment’s profit or loss, the amount and composition of any other segment items, the title and position of the CODM, and how the CODM uses the reported measure(s) of a segment’s profit or loss to assess performance and decide how to allocate resources. The amendments in this update are effective for fiscal years beginning after December 15, 2023. The adoption of this pronouncement is not expected to have a material impact on the Company’s condensed consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”, related to improvements to income tax disclosures. The amendments in this update require enhanced jurisdictional and other disaggregated disclosures for the effective tax rate reconciliation and income taxes paid. The amendments in this update are effective for fiscal years beginning after December 15, 2024. The adoption of this pronouncement is not expected to have a material impact on the Company’s condensed consolidated financial statements.

 

In November 2024, the FASB issued ASU 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures” to require more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this guidance on its condensed consolidated financial statements and related disclosures. The adoption of this pronouncement is not expected to have a material impact on the Company’s condensed consolidated financial statements.

 

11

 

 

The Company does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. 

 

Note 3. PROPERTY AND EQUIPMENT

 

The components of property and equipment at September 30, 2024 and December 31, 2023 consisted of the following:

 

   September 30,   December 31,     
   2024   2023     
             
Land  $300,000   $300,000      
Buildings and Improvements   2,712,000    2,206,000    31.5 years 
Machinery and Equipment   25,416,000    24,552,000    5 - 8 years 
Tools and Instruments   14,805,000    14,314,000    1.5 - 7 years 
Automotive Equipment   266,000    266,000    5 years 
Furniture and Fixtures   299,000    299,000    5 - 8 years 
Leasehold Improvements   1,126,000    1,025,000    Term of lease 
Computers and Software   605,000    605,000    4 - 6 years 
Total Property and Equipment   45,529,000    43,567,000      
Less: Accumulated Depreciation   (37,008,000)   (35,519,000)     
Property and Equipment, net  $8,521,000   $8,048,000      

 

Depreciation expense for the three months ended September 30, 2024 and 2023 was $511,000 and $614,000, respectively. Depreciation expense for the nine months ended September 30, 2024 and 2023 was $1,533,000 and $1,807,000, respectively. Assets held under financed lease obligations are depreciated over the shorter of their related lease terms or their estimated productive lives.

 

Note 4. OPERATING LEASE LIABILITIES

 

The Company has operating leases for leased office and manufacturing facilities. The leases have remaining lease terms of one to three years, some of which include options to extend or terminate the leases.

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30,   September 30,   September 30, 
   2024   2023   2024   2023 
Operating lease cost:  $326,000   $295,000   $966,000   $839,000 
Total lease cost  $326,000   $295,000   $966,000   $839,000 
                     
Other Information                    
Cash paid for amounts included in the measurement lease liability:   266,000    258,000    797,000    773,000 
Operating cash flow from operating leases  $266,000   $258,000   $797,000   $773,000 

 

   September 30,   December 31, 
   2024   2023 
Weighted Average Remaining Lease Term - in years   1.95    2.66 
Weighted Average discount rate - %   9.27%   9.10%

 

12

 

 

The aggregate undiscounted cash flows of operating lease payments as of September 30, 2024, with remaining terms greater than one year are as follows:

 

   Amount 
December 31, 2024 (remainder of year)  $273,000 
December 31, 2025   992,000 
December 31, 2026   729,000 
Total future minimum lease payments   1,994,000 
Less: discount   (179,000)
Total operating lease maturities   1,815,000 
Less: current portion of operating lease liabilities   (890,000)

Total long-term portion of operating lease maturities

  $925,000 

 

Note 5. DEBT

 

Total debt outstanding as of September 30, 2024 is $24,976,000 and was $23,310,000 at December 31, 2023.

 

Current credit facilities and finance lease obligations consist of the following:

 

   September 30,   December 31, 
   2024   2023 
         
Current Credit Facility - Revolver  $11,437,000   $10,804,000 
Current Credit Facility - Term Loan   5,401,000    5,045,000 
Solar Credit Facility   899,000    393,000 
Finance lease obligations   1,061,000    884,000 
Loans Payable - financed assets   16,000    22,000 
Subtotal   18,814,000    17,148,000 
Less: Current portion   (17,066,000)   (16,036,000)
Long-Term Portion  $1,748,000   $1,112,000 

 

Current Credit Facility

 

The Company has a credit facility (“Current Credit Facility”) with Webster Bank that expires on December 30, 2025. This facility, which was entered into on December 31, 2019, was amended several times (see summary of amendments below), and now provides for a $20,000,000 revolving loan (“Revolving Line of Credit”) and a $5,700,000 term loan (“Term Loan”). The loan is secured by a lien on substantially all of the assets of the Company.

 

As discussed in Note 1, the Company was in compliance with a required covenant as of September 30, 2024. However, there is no assurance that the Company will be able to meet its financial covenants in one of the upcoming fiscal quarters over the next twelve months, therefore, in accordance with the guidance in ASC 470-10-45, related to the classification of callable debt, the entire term loan has been classified as short term as of September 30, 2024.

 

The below table shows the timing of payments due under the Term Loan:

 

For the year ending  Amount 
December 31, 2024 (remainder of year)  $203,000 
December 31, 2025   5,225,000 
Term Loan payable   5,428,000 
Less: debt issuance costs   (27,000)
Total Term Loan payable, net of debt issuance costs   5,401,000 
Less: Current portion of Term Loan payable   (5,401,000)
Total long-term portion of Term Loan payable  $
-
 

 

13

 

 

Interest expense related to the Current Credit Facility amounted to approximately $332,000 and $380,000 for the three months ended September 30, 2024 and 2023, respectively, and $980,000 and $1,084,000 for the nine months ended September 30, 2024 and 2023, respectively. Interest expense includes the amortization of deferred finance costs of $17,000 and $17,000 for the three months ending September 30, 2024 and 2023, respectively, and $51,000 and $51,000 for the nine months ending September 30, 2024 and 2023, respectively.

 

The below summarizes various terms of the Current Credit Facility (all of which are described in full in various SEC filings):

 

The Company is required to achieve a defined EBITDA amount at the end of each Fiscal Quarter on a rolling basis. As of September 30, 2024, the Company achieved an EBITDA of $2,620,000 as compared to $1,500,000 that was required for the cumulative nine months period ending September 30, 2024.

 

For so long as the Term Loan remains outstanding, if Excess Cash Flow (as defined) is a positive number for any fiscal year the Company shall pay an amount equal to the lesser of (i) twenty-five percent (25%) of the Excess Cash Flow for such fiscal year and (ii) the outstanding principal balance of the term loan. Such payment shall be applied to the outstanding principal balance of the Term Loan, on or prior to the April 15 immediately following such fiscal year. For the fiscal year ended December 31, 2023, based on the calculation there was no Excess Cash Flow payment required.

 

Both the Revolving Line of Credit and the Term Loan will bear an interest rate equal to the greater of (i) 3.50% and (ii) a rate per annum equal to the rate per annum published from time to time in the “Money Rates” table of the Wall Street Journal (or such other presentation within The Wall Street Journal as may be adopted hereafter for such information) as the base or prime rate for corporate loans at the nation’s largest commercial bank, less sixty-five hundredths (-0.65%) of one percent per annum. The average interest rate charged was 7.78% for both the three months ended September 30, 2024 and 2023, and 7.83% and 7.44% for the nine months ended September 30, 2024 and 2023, respectively.

 

The Current Credit Facility limits the amount of capital expenditures and dividends the Company can pay to its stockholders. Substantially all of the Company’s assets are pledged as collateral.

 

The below summarizes certain historical amendments to the Current Credit Facility

 

On August 4, 2023, the Company entered into a Fifth Amendment that waived a default caused by the failure by the Company to meet the required Fixed Charge Coverage Ratio for the fiscal quarter ended March 31, 2023. Additionally, the amendment provided for a revised Fixed Charge Ratio for the fiscal quarters ending June 30, 2023, and September 30, 2023, and increased the amount of purchase money secured debt (such as finance leases) the Company is allowed to have outstanding at any time to $2,000,000. In connection with this amendment, the Company paid an amendment fee of $10,000.

 

On November 20, 2023, the Company entered into a Sixth Amendment that waived defaults caused by the Company’s failure to achieve the required Fixed Charge Coverage Ratio of the Fifth Amendment and because we made capital expenditures (as defined) in excess of permitted amounts. This amendment further revised the Fixed Charge Coverage Ratio by requiring it to be calculated on a rolling period basis and not be less than, (a)1.10x (as calculated on a six-months basis) for the fiscal quarter ending March 31, 2024 (b)1.20x (as calculated on a nine-months basis) for the fiscal quarter ending June 30, 2024, and (iv)1.25 (as calculated on a twelve-months basis) for all other fiscal quarters. This amendment also increased the Capital Expenditure limit to $2,500,000 in any fiscal year. In connection with these changes, the Company paid an amendment fee of $20,000.

 

On May 31, 2024, the Company entered into a Seventh Amendment that waived the default caused by the Company’s failure to achieve the Fixed Charge Coverage Ratio required by the Sixth Amendment. This amendment further revised the Financial Covenants. For the six months ending June30, 2024 EBITDA shall not be less than $740,000; for the nine months ending September 30, 2024 EBITDA shall not be less than $1,500,000; for the twelve months ending December 31, 2024 EBITDA shall not be less than $2,800,000. For the rolling twelve-month period ending March 31, 2025, the Company is required to achieve a Fixed Charge Coverage Ratio of 1.05x. Beginning with the rolling twelve-month period ending June 30, 2025 and forward the Company is required to achieve a Fixed Charge Coverage Ratio of 1.25x. All other covenants remain unchanged. Additionally, this amendment increased the Term Loan by approximately $1,000,000 to $5,700,000, with monthly principal installments in the amount of $68,000. In connection with these changes, the Company paid an amendment fee of $20,000.

 

14

 

 

All amendment fees paid in connection with the Current Credit Facility that are for a future benefit of the Company are included in Deferred Financing Costs, Net, Deposits and Other Assets, in the accompanying consolidated balance sheets and are amortized over the term of the loan.

 

As of September 30, 2024, the amount outstanding under the Company’s Revolving Line of Credit was $11,437,000, leaving $8,563,000 of availability to support the Company’s growth, subject to having the requisite collateral and maintaining compliance with the terms of the Credit Facility. 

 

Solar Credit Facility

 

On August 16, 2023, the Company entered into a financing agreement (“Solar Credit Facility”) with CT Green Bank, a quasi-public agency of the State of Connecticut, for the installation of solar energy systems including replacing the existing roof (“Project”) at its Sterling facility. Advances are made by CT Green Bank upon its approval of costs incurred on the Project up to $934,000. As of September 30, 2024, cumulative advances totaling $899,000 had been made including the payment of CT Green Bank’s closing costs of $25,000. Interest accrues at the rate of 5% on advances and is added to the loan upon conversion to a term loan.

 

On October 1, 2024, final disbursements were made on the financing arrangement in the amount of $35,000, bringing the cumulative advances to $934,000. The total cumulative advances along with the total accrued interest in the amount of $36,000 as of October 1, 2024 was converted by CT Green Bank, in accordance with the financing agreement, to a 20-year level payment term loan in the amount of $970,000 with interest accruing at the rate of 5.75%. Semi-annual payments in the amount of $42,000 are due commencing on July 1, 2025. The first semi-annual payment will be for interest only, subsequent semi-annual payments beginning with the payment due on January 1, 2026 will include both principal and interest. As of September 30, 2024, the amount classified as long term is $899,000 and the amount classified as current is $0.

 

Interest expense related to the Solar Credit Facility amounted to approximately $11,000 and $1,000 for the three months ended September 30, 2024 and 2023, respectively, and $30,000 and $1,000 for the nine months ended September 30, 2024 and 2023, respectively.  

 

Finance Lease Obligations

 

The Company has entered into finance leases for the purchase of additional manufacturing equipment. The obligations for the finance leases totaled $1,061,000 and $884,000 as of September 30, 2024 and December 31, 2023, respectively. The leases have an average imputed interest rate of 7.44% per annum and are payable monthly with the final payments due between September of 2026 and May of 2030.

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30,   September 30,   September 30, 
   2024   2023   2024   2023 
Finance Lease cost:                
   Amortization of Right-of-Use assets  $49,000   $21,000   $128,000   $46,000 
   Interest on lease liabilities   20,000    17,000    53,000    33,000 
Total lease Costs  $69,000   $38,000   $181,000   $79,000 
                     
Other Information:                    
Cash Paid for amounts included in the measurement lease liabilities:                    
   Financing cash flow from finance lease obligations  $51,000   $39,000   $143,000   $84,000 
                     
Supplemental disclosure of non-cash activity                    
   Acquisition of finance lease asset  $
-
   $679,000   $319,000   $679,000 

  

15

 

 

   September 30,   December 31, 
   2024   2023 
         
Weighted Average Remaining Lease Term - in years   5.0    5.4 
Weighted Average Discount rate - %   7.44%   7.31%

 

As of September 30, 2024, the aggregate future minimum finance lease payments, including imputed interest are as follows:

 

For the year ending  Amount 
December 31, 2024 (remainder of year)  $73,000 
December 31, 2025   291,000 
December 31, 2026   266,000 
December 31, 2027   190,000 
December 31, 2028   190,000 
Thereafter   264,000 
Total future minimum finance lease payments   1,274,000 
Less: imputed interest   (213,000)
Less: Current portion   (219,000)
Long-term portion  $842,000 

 

Loan Payable – Financed Asset

 

The Company financed the purchase of a delivery vehicle in July 2020. The loan obligation totaled $16,000 and $22,000 as of September 30, 2024 and December 31, 2023, respectively. The loan bears no interest and a final payment is due and payable for all unpaid principal on July 20, 2026.

 

The future minimum loan payments are as follows:

 

For the year ending  Amount 
December 31, 2024 (remainder of year)  $3,000 
December 31, 2025   9,000 
December 31, 2026   4,000 
Loans Payable - financed assets   16,000 
Less: Current portion   (9,000)
Long-term portion  $7,000 

 

Related Party Subordinated Notes Payable

 

Taglich Brothers, Inc. is a corporation co-founded by two directors of the Company, Michael and Robert Taglich. Taglich Brothers, Inc. has acted as placement agent for various debt and equity financing transactions and has received cash and equity compensation for their services.

 

From 2016 through 2020, the Company entered into various subordinated notes payable and convertible subordinated notes payable (together referred to as “Related Party Notes”) with Michael and Robert Taglich which generated proceeds to the Company totaling $6,550,000. In connection with these notes, Michael and Robert were issued a total of 35,508 shares of common stock and Taglich Brothers Inc. was issued promissory notes totaling $554,000 for placement agency fees.

 

16

 

 

The Related Party Notes outstanding as of the notes of September 30, 2024 and December 31, 2023 consist of:

 

   Michael Taglich, Chairman   Robert Taglich, Director   Taglich Brothers, Inc.   Total 
Convertible Subordinated Notes  $2,666,000   $1,905,000   $241,000   $4,812,000 
Subordinated Notes   1,000,000    350,000    
-
    1,350,000 
Total  $3,666,000   $2,255,000   $241,000   $6,162,000 

 

Of the $6,162,000, approximately $2,732,000 bears an annual rate of interest of 6%, $2,080,000 bears an annual rate of 7% and $1,350,000 bears an annual interest rate of 12%. Interest expense for the three months ended September 30, 2024 and 2023 on all related party subordinated notes payable was $118,000 and $118,000, respectively, and $354,000 and $354,000 for the nine months ended September 30, 2024 and 2023, respectively.

 

Approximately $2,732,000 of the convertible subordinated notes can be converted at the option of the holder into Common Stock of the Company at $15.00 per share, while the remaining $2,080,000 of the convertible subordinated notes can be converted at the option of the holder into common stock of the Company at $9.30 per share. The remaining $1,350,000 is not convertible. There are no principal payments due prior to July 1, 2026.

 

The Related Party Notes are subordinate to outstanding debt pursuant to the Current Credit Facility and mature on July 1, 2026. The Company is allowed, subject to certain limitation, to make principal payments of $250,000 to reduce the principal of the outstanding Related Party Subordinated Notes.

 

For the three and nine months ended September 30, 2024 and 2023, no principal payments have been made on these notes.

 

Note 6. STOCKHOLDERS’ EQUITY

 

Common Stock – Issuance of Securities

 

The Company issued 12,252 and 15,230 shares of common stock in payment of director fees totaling $40,000 and $54,000 for the three months ended September 30, 2024 and 2023, respectively, and 32,517 and 41,890 shares totaling $116,000 and $162,000 for the nine months ended September 30, 2024 and 2023, respectively.

 

The Company issued 13,754 and 15,229 shares, of common stock to net settle the exercise of stock options for three and nine months ended September 30, 2024, respectively. There were no issuances of common stock due to the exercise of stock options for the three and nine months ended September 30, 2023.

  

During the fourth quarter of 2024, the Company issued 7,328 shares of common stock in payment of directors’ fees totaling $39,000.

 

Note 7. STOCK OPTIONS AND RESTRICTED STOCK UNITS

 

Stock-Based Compensation

 

Stock Options

 

In September 2024, the shareholders of the Company approved the amendment to the 2022 Equity Incentive Plan (“2022 Plan”) to increase the number of shares authorized to be used under the plan by 300,000 shares, from 350,000 shares to 650,000 shares.

 

In September 2023, the shareholders of the Company approved the amendment to the 2022 Equity Incentive Plan (“2022 Plan”) to increase the number of shares authorized to be issued under the plan by 250,000 shares, from 100,000 shares to 350,000 shares. Additionally, this amendment to the 2022 Plan specified that the Company may grant Restricted Stock Units under the 2022 Plan.

 

17

 

 

During the three and nine months ended September 30, 2024, the Company granted options to purchase 80,000 shares of common stock to its directors. During the three and nine months ended September 30, 2023, the Company granted options to purchase 0 and 190,000 shares of common stock, respectively, to certain of its employees and directors.

 

The Company recorded stock-based compensation expense for certain employees and members of the Company’s Board of Directors of $87,000 and $28,000 for the three months ended September 30, 2024 and 2023, respectively and $122,000 and $260,000 for the nine months ended September 30, 2024 and 2023, respectively in its condensed consolidated statements of operations, and such amounts were included as a component of operating expenses.

 

The fair values of stock options granted were estimated using the Black-Sholes option-pricing model with the following assumptions for the nine months ended September 30:

 

   2024   2023 
Risk-free interest rates   3.80%   3.90%
Expected life (in years)   2.7    2.7 
Expected volatility   63.6%   61.0%
Dividend yield   0.00%   0.00%
           
Weighted-average grant date fair value per share  $3.75   $3.46 

  

The expected life is the number of years that the Company estimates, based upon history, that the options will be outstanding prior to exercise or forfeiture. Expected life is determined using the “simplified method” permitted by Staff Accounting Bulletin No. 107. In addition to the inputs referenced above regarding the option pricing model, the Company adjusts the stock-based compensation expense for estimated forfeiture rates that are revised prospectively according to forfeiture experience. The stock volatility factor is based on the Company’s experience.

 

A summary of the status of the Company’s stock options as of September 30, 2024 and December 31, 2023, and changes during the periods then ended are presented below.

 

   Options   Wtd. Avg. Exercise Price 
Balance, January 1, 2023   303,050   $11.70 
Granted during the period   189,620    3.46 
Exercised during the period   
-
    
-
 
Terminated/Expired during the period   (30,800)   13.60 
Balance, December 31, 2023   461,870   $8.34 
Granted during the period   80,000    3.75 
Exercised during the period   (32,867)   3.45 
Terminated/Expired during the period   (91,000)   9.84 
Balance, September 30, 2024   418,003   $7.01 
           
Exercisable at September 30, 2024   353,005   $7.63 

 

Issuance of Stock Options

 

Issued in 2024

 

On August 13, 2024, the Company granted to its directors, stock options to purchase an aggregate of 80,000 shares of the Company’s common stock at a price of $3.75 per share. The options expire on the fifth anniversary of the grant date and vest over a term of one year.

 

18

 

 

Issued in 2023

 

On May 23, 2023, the Company granted options to its directors and certain members of management and employees, stock options to purchase an aggregate of 108,620 shares of the Company’s common stock at a price of $3.43 per share. The options expire on the June 30, 2028 and vested immediately.

 

On June 2, 2023, the Company granted to its directors, stock options to purchase an aggregate of 6,000 shares of the Company’s common stock at a price of $3.50 per share. The options expire on the fifth anniversary of the grant date and vest over a term of one year.

 

On June 2, 2023, the Company granted to certain members of management and employees, stock options to purchase an aggregate of 75,000 shares of the Company’s common stock at a price of $3.50 per share. The options expire on the fifth anniversary of the grant date and vest over a term of three year.

 

The following table summarizes information about outstanding stock options at September 30, 2024:

  

Range of
Exercise Price
   Number
Outstanding
   Wtd. Avg, Life  Wtd. Avg.
Exercise Price
 
$3.46 - $15.60    418,003   2.8 Years  $ 7.63 

 

The following table summarizes information about outstanding stock options at December 31, 2023:

 

Range of
Exercise Price
   Number Exercisable   Wtd. Avg, Life  Wtd. Avg.
Exercise Price
 
$3.46 - $15.60    461,870   2.9 Years  $ 8.34 

  

As of September 30, 2024, there was $60,000 of unrecognized compensation cost related to non-vested stock option awards, which is to be recognized over the remaining weighted average vesting period of 0.75 years.

 

The aggregate intrinsic value at September 30, 2024 was based on the Company’s closing stock price of $5.50 was $478,000. The aggregate intrinsic value at December 31, 2023 was based on the Company’s closing stock price of $3.25 was approximately $0. The aggregate intrinsic value was calculated based on the positive difference between the closing market price of the Company’s Common Stock and the exercise prices of the underlying options.

 

The weighted average fair value of options granted during the periods ending September 30, 2024 and 2023 was $3.75 and $3.46 per share, respectively. The total intrinsic value of options exercised during the three months ended September 30, 2024 and 2023 was $87,500 and $0, respectively. The total intrinsic value of options exercised during the nine months ended September 30, 2024 and 2023 was $98,000 and $0, respectively. The total fair value of shares vested during the three months ended September 30, 2024 and 2023 was $63,000 and $70,000, respectively. The total fair value of shares vested during the nine months ended September 30, 2024 and 2023 was $181,000 and $415,000, respectively.

 

19

 

 

Restricted Stock Units (“RSUs”)

 

During the three and nine months ended September 30, 2024 and 2023, the Company granted 282,628 and 0 RSUs to certain employees. These Restricted Stock Units vest solely on the passage of times and continued service through the vesting dates.

 

A summary of the status of the Company’s RSUs as of September 30, 2024 is presented below.

 

   Number of
Units
   Wtd. Avg. Grant Date
Fair Value
per Unit
 
Unvested units as of January 1, 2024   
-
   $
-
 
Granted during the period   282,628    6.06 
Vested during the period   
-
    
-
 
Forfeited During the period   
-
    
-
 
Unvested Units as of September 30, 2024   282,628   $6.06 
           
Vested as of September 30, 2024   
-
   $
-
 

 

The Company recorded stock-based compensation expense of $63,000 and $0 for the three and nine months ended September 30, 2024 and 2023, respectively, in its condensed consolidated statements of operations, and such amounts were included as a component of operating expenses.

 

As of September 30, 2024, there was $1,649,000 of unrecognized compensation cost related to non-vested RSUs, which is to be recognized over the remaining weighted average vesting period of 2.5 years.

 

20

 

 

Note 8. COMMITMENTS AND CONTINGENCIES

 

On October 2, 2018, Contract Pharmacal Corp. (“Contract Pharmacal”) commenced an action, relating to a Sublease entered into between the Company and Contract Pharmacal in May 2018 with respect to the property that was formerly occupied by the Company’s former subsidiary WMI, at 110 Plant Avenue, Hauppauge, New York. In the action, Contract Pharmacal sought damages for an amount in excess of $1,000,000 for the Company’s alleged violation of the terms of the subject sublease, specifically the failure to make the entire premises available by the Sublease commencement date. The validity of the action is extremely suspect in that the subject sublease had no specific commencement date and Contract Pharmacal ultimately received all the space. Discovery was conducted and the Plaintiff moved for summary judgement and to amend its complaint to add a new cause of action all of which the company opposed.  On July 8, 2021, the Court denied Contract Phamacal’s motion for summary judgement and to add an additional cause of action. In the Order, the Court granted Contract Pharmacal’s Motions to drop its claim for specific performance and to amend its Complaint to reduce its claim for damages to $700,000 both of which benefit the Company. Following the Court’s decision, Contract Pharmacal filed a Motion to reargue its original motion which the Company again opposed.  The Court denied that motion on November 30, 2021 and then on March 10, 2022, Contract Pharmacal filed an appeal of the Court’s decision with the Appellate Division of the State of New York. Once again, the Company opposed that action.  The Company was again successful as the Appellate Division upheld the lower court’s denial of Contract Pharmacal’s motion for summary judgement and its motion to amend its Complaint.  Contract Pharmacal has now submitted a motion to the Appellate Division requesting leave to reargue the court’s denial of its original appeal.  The Company will oppose that motion to reargue.   The Company continues to dispute the validity of the claims asserted by Contract Pharmacal and intends to contest them vigorously. We anticipate that due to this newest action by Contract Pharmacal nothing of consequence will happen over the next twelve months.

 

From time to time the Company may be engaged in various lawsuits and legal proceedings in the ordinary course of business. The Company is currently not aware of any legal proceedings the ultimate outcome of which, in its judgment based on information currently available, would have a material adverse effect on its business, financial condition or operating results. There are no proceedings in which any of the Company’s directors, officers or affiliates, or any registered or beneficial stockholder of its common stock, is an adverse party or has a material interest adverse to our interest.

 

Note 9. INCOME TAXES

 

The Company recorded no income tax expense for the three and nine months ended September 30, 2024 and 2023 because the estimated annual effective tax rate was zero. In determining the estimated annual effective income tax rate, the Company analyzes various factors, including projections of the Company’s annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.

 

As of September 30, 2024, and December 31, 2023, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

 

21

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and notes to those statements included elsewhere in this Form 10-Q and with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K, for the year ended December 31, 2023 (the “2023 Form 10-K”). This discussion contains forward-looking statements that involve risks and uncertainties. You should specifically consider the various risk factors identified in this report and our 2023 Form 10-K that could cause actual results to differ materially from those anticipated in these forward-looking statements.

 

Business Overview

 

We believe we are one of the leading manufacturers of precision components and assemblies for large aerospace and defense contractors. Our rich history dates to 1941, producing parts for World War II fighter aircraft. Since then, we have maintained an impeccable record with no known incidents of part failure leading to a fatal mission. We became a public company in 2005.

 

Our products include landing gear, flight controls, engine mounts and components for aircraft jet engines and ground turbines and other complex machines. The ultimate end-user for most of our products is the U.S. government, foreign governments, and commercial global airlines. Whether it is a small individual component for assembly by others or complete assemblies we manufacture ourselves, our high quality and extremely reliable products are used in mission critical operations that are essential for safety of military personnel and civilians.

 

Although our net sales are concentrated amongst a number of defense and aerospace prime contractors, we have cultivated long-standing relationships with a number of their subsidiaries and/or business units. Additionally, our net sales are generated across several high-profile platforms and programs including: the F-18 Hornet, the E-2 Hawkeye, the UH-60 Black Hawk Helicopters, Geared Turbo Engines (used on smaller aircraft such as the Airbus A220 and Embraer E2), the CH-53 Helicopter, the F-35 Lighting II and the F-15 Eagle Tactical Fighter. In many cases, we are the sole or single supplier of certain parts and components and receive LTAs from our customers, both demonstrating their commitment to us.

 

Winning a new contract award is highly competitive. Our ability to win new contract awards generally requires us to deliver superior quality products, more quickly and with lower pricing than our competitors. Accordingly, we must continually invest in process improvements and capital equipment. Recent investments in new equipment have improved the productive capacity of our employees, increased our efficiency and speed, and expanded the size of products we can manufacture. We strategically operate two state-of-the-art manufacturing centers in the U.S. This allows for rigorous oversight of production and the adherence to stringent quality standards. Although there is currently a shortage of skilled workers, we maintain a highly trained and close knit team of over 180 professionals committed to driving excellence and precision in every aspect of our operations.

 

Our period-to-period net sales and operating results are significantly impacted by timing. In addition, our gross profit is affected by a variety of factors, including the mix and complexity of products, production efficiencies, price competition and general business operating environments. In some cases, our gross profit is impacted by our ability to deliver replacement parts on short notice. Our operations have a large percentage of fixed factory overhead. As a result, our profit margins are highly variable with sales volumes.

 

For the past several years, despite facing significant financial and operational challenges, we have strategically invested substantial amounts in new capital equipment, tooling, and processes to bolster our competitive position. Additionally, we expanded our sales and marketing efforts, with a sharp focus on expanding relationships with existing customers and cultivating new ones. Fiscal 2023 marked a year of overall progress and positioning for growth. During the first nine months of 2024 and looking forward, our business strategy is geared towards achieving sustainable and profitable business growth. We are firmly focused on securing new contract awards, improving operations and successful execution.

 

With total unfilled contract values amounting to $175.7 million (including our $105.2 million in backlog and all potential orders against LTA agreements previously awarded to us), as of September 30, 2024, we are confident in our ability to boost sales during the remainder of 2024, attain profitability and improve our financial position.

  

22

 

 

RESULTS OF OPERATIONS

  

Selected Financial Information:

 

   Three Months Ending
September 30, 2024
   2024 Percentage of Net Sales   Three Months Ending
September 30, 2023
   2023 Percentage of Net Sales   Change 2024 vs 2023   Percent Change 2024 vs 2023 
                         
Net sales  $12,555,000    100.0%  $12,293,000    100.0%  $262,000    2.1%
Cost of sales   10,614,000    84.5%   11,065,000    90.0%   (451,000)   -4.1%
Gross profit   1,941,000    15.5%   1,228,000    10.0%   713,000    58.1%
Operating expenses   1,874,000    14.9%   2,024,000    16.5%   (150,000)   -7.4%
Interest expense   482,000    3.8%   516,000    4.2%   (34,000)   -6.6%
Other income, net   11,000    0.1%   13,000    0.1%   (2,000)   -15.4%
Provision for income taxes   -    0.0%   -    0.0%   -    0.0%
Net loss  $(404,000)   -3.2%  $(1,299,000)   -10.6%  $895,000    -68.9%

 

   Nine Months Ending
September 30, 2024
   2024 Percentage of Net Sales   Nine Months Ending
September 30, 2023
   2023 Percentage of Net Sales   Change 2024 vs 2023   Percent Change 2024 vs 2023 
                         
Net sales  $40,188,000    100.0%  $38,047,000    100.0%  $2,141,000    5.6%
Cost of sales   33,697,000    83.8%   32,769,000    86.1%   928,000    2.8%
Gross profit   6,491,000    16.2%   5,278,000    13.9%   1,213,000    23.0%
Operating expenses   5,931,000    14.8%   6,160,000    16.2%   (229,000)   -3.7%
Interest expense   1,418,000    3.5%   1,472,000    3.9%   (54,000)   -3.7%
Other income, net   46,000    0.1%   42,000    0.1%   4,000    9.5%
Provision for income taxes   -    0.0%   -    0.0%   -    0.0%
Net loss  $(812,000)   -2.0%  $(2,312,000)   -6.1%  $1,500,000    -64.9%

 

Balance Sheet Data:

 

   September 30,   December 31,       Percent 
   2024   2023   Change   Change 
                 
Cash  $186,000   $346,000    (160,000)   -46.2%
Working capital  $11,807,000   $12,117,000    (310,000)   -2.6%
Total assets  $50,365,000   $50,715,000    (350,000)   -0.7%
Total stockholders’ equity  $14,680,000   $15,190,000    (510,000)   -3.4%

  

Results of Operations for the three months ended September 30, 2024

 

Net Sales: Net sales for the three months ended September 30, 2024 were $12,555,000, an increase of $262,000, or 2.1%, compared with $12,293,000 that we achieved in the three months ended September 30, 2023. The period-over-period increase in net sales was primarily due to overall changes in the mix of products requested by customers, which are discussed further below.

23

 

 

The composition of customers that exceeded 10% of our net sales for 2024 and 2023 are shown below: 

 

  Percentage of Net Sales 
Customer  2024   2023 
RTX (a)   27.8%   20.1%
Lockheed   23.9%   31.9%
Northrop   18.3%   - 
Boeing   -    18.0%

 

(a)RTX includes Collins Landing Systems and Collins Aerostructures

 

The composition of our net sales by platform or program profiles for the three months ended September 30, 2024 and 2023 are shown below:

 

   Percentage of Net Sales 
Platform or Program  2024   2023 
GTF   27.2%   10.9%
E2-D Hawkeye   24.5%   9.6%
UH-60 Black Hawk Helicopter   21.2%   22.8%
CH-53 Helicopter   5.8%   6.5%
F-35 Lightning II   2.0%   3.5%
F-18 Hornet   1.5%   31.7%
All other platforms   17.8%   15.0%
Total   100.0%   100.0%

  

Period-to-period changes in customer mix and related platforms and programs are largely attributable to customer requirements, availability of parts, production capacity and timing.

 

Gross Profit: Gross profit for the three months ended September 30, 2024, was $1,941,000 as compared to $1,228,000 for the three months ended September 30, 2023. Our gross profit percentage for the three months ended September 30, 2024 increased to 15.5% from the 10.0% for the three months ended September 30, 2023. The increase in margin can be attributable to changes in the sales across our major platforms, shifts in product mix, and overall operating efficiencies.

 

Operating Expenses: Operating expenses was $1,874,000, for the three months ended September 30, 2024, a decrease of $150,000, from $2,024,000 for the three months ended September 30, 2023. As a percentage of consolidated net sales, operating expenses decreased to 14.9%, compared to the 16.5% achieved during the three months ended September 30, 2023. The dollar decrease was primarily driven by reductions in stock compensation expense and our allowance for credit loss, offset by increases in costs associated with the continued improvement of our information technology system and hardening our cyber-security defenses. We continue to look for ways to reduce our costs and improve our operating performance and financial results.

 

Interest Expense: Interest expense (which includes amortization of deferred financing costs) was $482,000 during the three months ended September 30, 2024, a decrease of $34,000 or 6.6% from $516,000 during the three months ended September 30, 2023. The decrease is primarily attributable to lower borrowing levels during a portion of the period.

 

Net Loss: Net loss for the three months ended September 30, 2024 was $404,000, compared to a net loss of $1,299,000 for the three months ended September 30, 2023, for the reasons discussed above.

 

24

 

 

Results of Operations for the nine months ended September 30, 2024

 

Net Sales: Consolidated net sales for the nine months ended September 30, 2024 were $40,188,000, an increase of $2,141,000, or 5.6%, compared with $38,047,000 that we achieved in the nine months ended September 30, 2023. The period-over-period increase in net sales was primarily due to overall changes in the mix of products requested by customers, which are discussed further below.

 

The composition of customers that exceeded 10% of our net sales for 2024 and 2023 are shown below:

  

  Percentage of Net Sales 
Customer  2024   2023 
RTX (a)   27.0%   26.6%
Lockheed   25.1%   24.7%
Northrop   19.9%   2.6%
Ruag   1.5%   10.9%
Boeing   0.3%   10.0%

 

(a)RTX includes Collins Landing Systems and Collins Aerostructures

 

The composition of our net sales by platform or program profiles for the nine months ended September 30, 2024 and 2023 are shown below:

 

   Percentage of Net Sales 
Platform or Program  2024   2023 
E2-D Hawkeye   26.9%   18.0%
UH-60 Black Hawk Helicopter   22.0%   17.1%
GTF   22.0%   9.3%
CH-53 Helicopter   4.4%   8.9%
F-35 Lightning II   3.3%   4.4%
F-18 Hornet   3.3%   24.5%
All other platforms   18.1%   17.8%
Total   100.0%   100.0%

  

Gross Profit: Gross profit for the nine months ended September 30, 2024, was $6,491,000 as compared to $5,278,000 for the nine months ended September 30, 2023. Our gross profit percentage for the nine months ended September 30, 2024 increased to 16.2% from the 13.9% for the nine months ended September 30, 2023. The increase in margin can be attributable to changes in sales across our major platforms, shifts in product mix, and overall operating efficiencies.

 

Operating Expenses: Operating expenses were $5,931,000, for the nine months ended September 30, 2024, a decrease of $229,000, from $6,160,000 for the nine months ended September 30, 2023. As a percentage of consolidated net sales, operating expenses decreased to 14.8%, compared to the 16.2% incurred during the nine months ended September 30, 2023. The dollar decrease was primarily driven by reductions in stock compensation expense and our allowance for credit loss, offset by costs associated with the continued improvement of our information technology system and hardening our cyber-security defenses. We continue to look for ways to reduce our costs and improve our operating performance and financial results.

 

Interest Expense: Interest expense (which includes amortization of deferred financing costs) was $1,418,000 during the nine months ended September 30, 2024, a decrease of $54,000 or 3.7% from $1,472,000 during the nine months ended September 30, 2023. The decrease is primarily attributable to lower borrowing levels during a portion of the period, partially offset by an increase in the average interest rate on outstanding debt pursuant to our Current Credit Facility which increased to 7.83% in 2024 as compared to 7.44% in 2023.

 

25

 

 

Net Loss: Net Loss for the nine months ended September 30, 2024 was $812,000, compared to a net loss of $2,312,000 for the nine months ended September 30, 2023, for the reasons discussed above. 

 

LIQUIDITY AND CAPITAL RESOURCES

 

As of September 30, 2024, we have debt service requirements related to:

 

1)Outstanding indebtedness under our Current Credit Facility of $16,838,000 (consisting of a Revolving Loan of $11,437,000 and a Term Loan of $5,401,000). This debt matures on December 30, 2025, and requires us to make monthly payments on the term loan of approximately $68,000 until the loan matures.

 

2)Related Party Notes of approximately $6,162,000. This debt matures on July 1, 2026. Pursuant to the Current Credit Facility we are permitted to make principal payments against this debt in the amount of $250,000 per quarter, as long as certain conditions are met.

 

3)Various equipment leases and contractual obligations related to our business, including advances under our Solar Facility for the installation of solar energy systems including the replacement of the existing roof at our Sterling Facility.

 

Under the terms of the Current Credit Facility, as amended, we are required to achieve EBITDA (as defined in the Current Credit Facility) at the end of each Fiscal Quarter on a rolling basis, for the Fiscal Quarters ending September 30, 2024 and December 31, 2024. Beginning with the Fiscal Quarter ending March 31, 2025 we are required to meet a Fixed Charge Coverage Ratio (as defined) that is determined at the end of each fiscal quarter. This ratio is a financial metric that we use to measure our ability to cover fixed charges such as interest and lease expenses as divided by EBITDA (as defined in the Current Credit Facility) which represents net income (loss) before interest, taxes, depreciation and amortization. For the nine months cumulative period ending September 30, 2024, we achieved an EBITDA of $2,620,000 as compared to the $1,500,000.

 

We obtained a waiver of the requirement to meet the Fixed Charge Coverage Ratio at March 31, 2024, and met the financial covenants as of both June 30, 2024 and September 30, 2024. Nevertheless, we may fail to achieve the required covenants in the future. Therefore, we have classified the term loan that expires on December 30, 2025 as current as of September 30, 2024, in accordance with the guidance in ASC 470-10-45, “Debt – Other Presentation Matters”, related to the classification of callable debt. We are required to maintain a collection account with our lender into which substantially all of our cash receipts are remitted. If we were to default under our Current Credit Facility, our lender could choose to increase the rate of interest we pay or refuse to make loans under the revolving portion of the Facility and keep the funds remitted to the collection account. If the lender were to raise the rate of interest we pay, it would adversely impact our operating results. If the lender were to cease making new loans under our revolving facility, we would lack the funds to continue our operations. The rights granted to our lender under the Current Credit Facility combined with the possibility that we might fail to meet covenants in the future raise substantial doubt about our ability to continue as a going concern for the one year commencing as of the issuance of these condensed consolidated financial statements.

 

The following is a brief discussion of recent amendments to the Current Credit Facility (all of which have been filed with the SEC):

 

On August 4, 2023, we entered into a Fifth Amendment that waived a default caused by our failure to meet the required Fixed Coverage Charge Ratio for the fiscal quarter ended March 31, 2023. Additionally, the amendment provided for a revised Fixed Coverage Charge Ratio for the fiscal quarters ending June 30, 2023 and September 30, 2023 and increased the amount of purchase money secured debt (or finance leases) we are allowed to have outstanding at any time to $2,000,000. In connection with this amendment, we paid a fee of $10,000.

 

26

 

 

On November 20, 2023, we entered into a Sixth Amendment that waived defaults caused by our failure to achieve the Fixed Charge Coverage Ratio of the Fifth Amendment and because we made capital expenditures (as defined) in excess of permitted amounts. This amendment further revised the Fixed Charge Coverage Ratio by requiring it to be calculated on a rolling period basis and not be less than, (a) 1.10x (as calculated on a six-months basis) for the fiscal quarter ending March 31, 2024, (b) 1.20x (as calculated on a nine-months basis) for the fiscal quarter ending June 30, 2024, and (c) 1.25 (as calculated on a twelve-months basis) for all fiscal quarters beginning with September 30, 2024, until the Current Credit Facility expires. This amendment also increased our ability to make additional capital expenditures up to a limit of $2,000,000 in any fiscal year. In connection with this amendment, we paid a fee of $20,000.

 

On May 31, 2024, we entered into a Seventh Amendment that waived the default caused by our failure to achieve the required Fixed Charge Coverage Ratio of the Sixth Amendment. This amendment further revised our Financial Covenants. For the six months ending June 30, 2024 our EBITDA shall not be less than $740,000; for the nine months ending September 30, 2024 our EBITDA shall not be less than $1,500,000; for the twelve months ending December 31, 2024 our EBITDA shall not be less than $2,800,000. For the rolling twelve month period ending March 31, 2025, we are required to achieve a Fixed Charge Coverage Ratio of 1.05x. Beginning with the rolling twelve month period ending June 30, 2025 and going forward the Company is required to achieve a Fixed Charge Coverage Ratio of 1.25x. All other covenants remain unchanged. Additionally, this amendment increased the Term Loan by approximately $1,000,000 to $5,700,000, with monthly principal installments in the amount of $68,000. In connection with these changes, the Company paid an amendment fee of $20,000.

 

In addition to required Term Loan payments of approximately $204,000 for the remainder of fiscal 2024, we may have to make additional payments. For so long as the Term Loan under the Current Credit Facility remains outstanding, if Excess Cash Flow (as defined) is a positive amount for any fiscal year, we are obligated to pay an amount equal to the lesser of (i) twenty-five percent (25%) of the Excess Cash Flow and (ii) the outstanding principal balance of the Term Loan. Such payment shall be applied to the outstanding principal balance of the Term loan, on or prior to the April 15 immediately following such fiscal year. For the fiscal year ended December 31, 2023, based on the calculation there was no Excess Cash Flow payment required.

 

In addition to the outstanding indebtedness under the Current Credit Facility and Related Party Notes, we have various equipment leases and contractual obligations of an ongoing nature which we service in the ordinary course out of our cash flow from operations.

 

Our material cash requirements are for debt service, capital expenditures and working capital. We have historically met these requirements with funds provided by a combination of cash generated from operating activities and cash generated from equity and debt financing transactions. Although navigating the current business landscape remains challenging and it is difficult to predict period-to-period financial performance, based on our current revenue visibility and the strength of our backlog, we believe we have sufficient liquidity to meet our financial obligations for the next twelve months from the date of issuance of our condensed consolidated financial statements included in this Quarterly Report. However, if we were to default under our Current Credit Facility and were unable to obtain a waiver from our lender and it was to cease lending we would not be able to meet our financial obligations. As of September 30, 2024, the amount outstanding under our Revolving Line of Credit was $11,437,000, leaving $8,563,000 of availability to support our growth, subject to having the requisite collateral and maintaining compliance with the terms of the Credit Facility.

 

27

 

 

Cash Flow

 

The following table summarizes our net cash flow from operating, investing and financing activities for the periods indicated below (in thousands):

 

   Nine months ended 
   September 30, 
   2024   2023 
         
Cash provided by (used in)        
Operating activities  $508   $7,093 
Investing activities   (1,493)   (1,867)
Financing activities   825    (4,767)
Net (decrease) increase in cash  $(160)  $459 

 

Cash Provided by Operating Activities

 

For the nine months ended September 30, 2024, we generated $508,000 of cash flows from operations as compared to $7,093,000 for the nine months ended September 30, 2023. The reduction was due primarily to the use of a portion of customer deposits which had been advanced in 2023 for the procurement of long lead time raw materials expected to be utilized during 2024.

 

For the nine months ended September 30, 2023, we generated cash of $7,093,000 from operations which was mainly attributable to a substantial decrease in accounts receivable and an increase in customer deposits.

 

Cash Used in Investing Activities

 

During the first nine months of 2024, we continued to make investments to enhance our competitiveness and market position. Cash used in investing activities of $1,493,000 and $1,867,000, during the nine months ended September 30, 2024 and 2023, respectively, was for new property and equipment. Investments in 2024 and 2023 increased our production efficiency and speed, while enabling us to maintain closer tolerances. They also expanded the size of products we can manufacture.

 

During fiscal 2024, we expect to continue to make strategic investments in capital equipment to enhance our competitiveness. We expect to invest approximately an additional $750,000 during the remainder of 2024 for new or upgraded equipment.

 

Cash Provided by (Used in) Financing Activities

 

For the nine months ended September 30, 2024, cash provided by financing activities was $825,000. During this period, we increased borrowings under our Current Credit Facility by $974,000 (consisting of a net increase in Revolving Loan borrowings of $633,000 and a net increase in our Term Loan of $341,000). We also made payments of $143,000 pursuant to financing lease obligations and $6,000 on a loan payable.

 

For the nine months ended September 30, 2023, cash used in financing activities was $4,767,000. During this period, we decreased our borrowings under our Current Credit Facility by $5,784,000 (consisting of a net decrease in Revolving Loan borrowings of $ $4,908,000, and a net decrease of $876,000 in the Term Loan).We also made payments of $84,000 pursuant to financing lease obligations and $7,000 on a loan payable. Additionally, there were advances totaling $393,000 taken on our financing agreement from CT Green Bank.

 

28

 

 

OFF-BALANCE SHEET ARRANGEMENTS

 

We did not have any off-balance sheet arrangements as of September 30, 2024.

 

Critical Accounting Estimates

 

A critical accounting estimate is one that is both important to the portrayal of a company’s financial condition and results of operations and requires management’s most difficult, subjective or complex judgements, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

 

Use of Estimates. The preparation of financial statements in accordance with generally accepted accounting principles in the U.S. requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and our judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include, inventory valuation, useful lives and impairment of long-lived assets, income tax provision, and allowance for credit losses. Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.

 

There have been no material changes to the Company’s critical accounting estimates as compared to the estimates described in the 2023 Annual Report which we believe are the most critical to our business and understanding of our results of operations and affect the more significant judgments and estimates that we use in preparation of our condensed consolidated financial statements.

  

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting refers to those policies, procedures and processes that pertain to the maintenance of records that accurately and fairly reflect transactions with respect to our assets; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures are made only in accordance with authorizations of our management; and provide reasonable assurance regarding the prevention and timely detection of unauthorized transactions with respect to our assets that could have a material effect on our financial statements.

 

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Our management relies upon the criteria established in the Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) in designing a system intended to meet the needs of our Company and provide reasonable assurance for its assessment.

 

 In connection with their review of our internal controls over financial reporting as of the end of the nine months ended September 30, 2024, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls over financial reporting were not effective as of September 30, 2024. As reported in our 2023 Form 10-K, in connection with their review of our internal controls as of and for the year ended December 31, 2023, our management identified a material weakness in our internal controls over financial reporting related to our IT systems which has yet to be remediated. During fiscal 2023 and continuing in fiscal 2024, we implemented new controls and procedures to eliminate this weakness and are continuing to test their effectiveness. Tests of such controls and procedures are ongoing and the material weakness noted will only be deemed to have been remediated after the new controls and procedures have been in place for a sufficient period and management has concluded through appropriate testing that the controls are operating effectively. For more information, see Item 9A. Controls and Procedures, included in our Annual Report on Form 10-K.

 

Changes in Internal Control over Financial Reporting

 

Except for the ongoing changes described above intended to remediate the material weakness with respect to our IT System, there have not been any changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter which is the subject of this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.  

 

29

 

 

PART II

 

OTHER INFORMATION

 

Item 1A. Risk Factors.

 

Investors are encouraged to consider the risks described in our 2023 Form 10-K, our Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this Report and other information publicly disclosed or contained in documents we file with the Securities and Exchange Commission before purchasing our securities.

  

Item 6. Exhibits

   

Exhibit No.    Description
     
31.1   Certification of principal executive officer pursuant to Rule 13a-14 or Rule 15d-14 of Securities Exchange Act of 1934.
     
31.2   Certification of principal financial officer pursuant to Rule 13a-14 or Rule 15d-14 of the Exchange Act of 1934.
     
32.1   Certification of principal executive officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).
     
32.2   Certification of principal financial officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).
     
    XBRL Presentation
     
101.INS   XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

30

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: November 14, 2024

 

  AIR INDUSTRIES GROUP
     
  By: /s/ Scott Glassman
    Scott Glassman
Chief Financial Officer
(principal financial and accounting officer)

 

 

31

 

 

NYSEAMER http://fasb.org/us-gaap/2024#FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList false --12-31 Q3 0001009891 0001009891 2024-01-01 2024-09-30 0001009891 2024-11-12 0001009891 2024-09-30 0001009891 2023-12-31 0001009891 us-gaap:RelatedPartyMember 2024-09-30 0001009891 us-gaap:RelatedPartyMember 2023-12-31 0001009891 2024-07-01 2024-09-30 0001009891 2023-07-01 2023-09-30 0001009891 2023-01-01 2023-09-30 0001009891 us-gaap:RelatedPartyMember 2024-07-01 2024-09-30 0001009891 us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001009891 us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0001009891 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001009891 us-gaap:CommonStockMember 2023-12-31 0001009891 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001009891 us-gaap:RetainedEarningsMember 2023-12-31 0001009891 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001009891 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001009891 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001009891 2024-01-01 2024-03-31 0001009891 us-gaap:CommonStockMember 2024-03-31 0001009891 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001009891 us-gaap:RetainedEarningsMember 2024-03-31 0001009891 2024-03-31 0001009891 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001009891 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001009891 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001009891 2024-04-01 2024-06-30 0001009891 us-gaap:CommonStockMember 2024-06-30 0001009891 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001009891 us-gaap:RetainedEarningsMember 2024-06-30 0001009891 2024-06-30 0001009891 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001009891 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001009891 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001009891 us-gaap:CommonStockMember 2024-09-30 0001009891 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001009891 us-gaap:RetainedEarningsMember 2024-09-30 0001009891 us-gaap:CommonStockMember 2022-12-31 0001009891 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001009891 us-gaap:RetainedEarningsMember 2022-12-31 0001009891 2022-12-31 0001009891 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001009891 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001009891 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001009891 2023-01-01 2023-03-31 0001009891 us-gaap:CommonStockMember 2023-03-31 0001009891 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001009891 us-gaap:RetainedEarningsMember 2023-03-31 0001009891 2023-03-31 0001009891 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001009891 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001009891 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001009891 2023-04-01 2023-06-30 0001009891 us-gaap:CommonStockMember 2023-06-30 0001009891 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001009891 us-gaap:RetainedEarningsMember 2023-06-30 0001009891 2023-06-30 0001009891 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001009891 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001009891 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001009891 us-gaap:CommonStockMember 2023-09-30 0001009891 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001009891 us-gaap:RetainedEarningsMember 2023-09-30 0001009891 2023-09-30 0001009891 us-gaap:LineOfCreditMember 2024-09-30 0001009891 us-gaap:LineOfCreditMember 2023-01-01 2023-12-31 0001009891 airi:TermLoanMember 2024-01-01 2024-09-30 0001009891 airi:TermLoanMember 2024-09-30 0001009891 airi:TermLoanMember 2023-12-31 0001009891 airi:CustomerDepositMember 2024-07-01 2024-09-30 0001009891 airi:CustomerDepositMember 2024-01-01 2024-09-30 0001009891 airi:CustomerDepositMember 2023-07-01 2023-09-30 0001009891 airi:CustomerDepositMember 2023-01-01 2023-09-30 0001009891 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-07-01 2024-09-30 0001009891 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-07-01 2023-09-30 0001009891 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-09-30 0001009891 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-01-01 2023-09-30 0001009891 srt:DirectorMember 2024-07-01 2024-09-30 0001009891 srt:DirectorMember 2023-07-01 2023-09-30 0001009891 srt:DirectorMember 2024-01-01 2024-09-30 0001009891 srt:DirectorMember 2023-01-01 2023-09-30 0001009891 airi:RTXMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001009891 airi:RTXMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001009891 airi:LockheedMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001009891 airi:LockheedMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001009891 airi:NorthropMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001009891 airi:NorthropMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001009891 airi:BoeingMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001009891 airi:BoeingMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001009891 airi:RTXMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001009891 airi:RTXMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001009891 airi:LockheedMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001009891 airi:LockheedMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001009891 airi:NorthropMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001009891 airi:NorthropMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001009891 airi:RuagMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001009891 airi:RuagMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001009891 airi:BoeingMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001009891 airi:BoeingMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001009891 us-gaap:AccountsReceivableMember 2024-01-01 2024-09-30 0001009891 airi:RTXMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-01-01 2024-09-30 0001009891 airi:RTXMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001009891 airi:LockheedMartinMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-01-01 2024-09-30 0001009891 airi:LockheedMartinMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001009891 airi:NorthropMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-01-01 2024-09-30 0001009891 airi:NorthropMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001009891 airi:BoeingMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-01-01 2024-09-30 0001009891 airi:BoeingMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001009891 airi:MilitaryMember 2024-07-01 2024-09-30 0001009891 airi:MilitaryMember 2023-07-01 2023-09-30 0001009891 airi:MilitaryMember 2024-01-01 2024-09-30 0001009891 airi:MilitaryMember 2023-01-01 2023-09-30 0001009891 airi:CommercialMember 2024-07-01 2024-09-30 0001009891 airi:CommercialMember 2023-07-01 2023-09-30 0001009891 airi:CommercialMember 2024-01-01 2024-09-30 0001009891 airi:CommercialMember 2023-01-01 2023-09-30 0001009891 us-gaap:StockOptionMember us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001009891 us-gaap:StockOptionMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001009891 us-gaap:StockOptionMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001009891 us-gaap:StockOptionMember us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001009891 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001009891 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001009891 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001009891 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001009891 us-gaap:StockOptionMember 2024-07-01 2024-09-30 0001009891 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001009891 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001009891 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001009891 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001009891 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001009891 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001009891 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001009891 us-gaap:ConvertibleDebtSecuritiesMember 2024-07-01 2024-09-30 0001009891 us-gaap:ConvertibleDebtSecuritiesMember 2023-07-01 2023-09-30 0001009891 us-gaap:ConvertibleDebtSecuritiesMember 2024-01-01 2024-09-30 0001009891 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-09-30 0001009891 us-gaap:LandMember 2024-09-30 0001009891 us-gaap:LandMember 2023-12-31 0001009891 us-gaap:BuildingAndBuildingImprovementsMember 2024-09-30 0001009891 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0001009891 us-gaap:MachineryAndEquipmentMember 2024-09-30 0001009891 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001009891 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-09-30 0001009891 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-09-30 0001009891 airi:ToolsAndInstrumentsMember 2024-09-30 0001009891 airi:ToolsAndInstrumentsMember 2023-12-31 0001009891 srt:MinimumMember airi:ToolsAndInstrumentsMember 2024-09-30 0001009891 srt:MaximumMember airi:ToolsAndInstrumentsMember 2024-09-30 0001009891 airi:AutomotiveEquipmentMember 2024-09-30 0001009891 airi:AutomotiveEquipmentMember 2023-12-31 0001009891 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001009891 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001009891 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2024-09-30 0001009891 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2024-09-30 0001009891 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001009891 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001009891 us-gaap:LeaseholdImprovementsMember 2024-01-01 2024-09-30 0001009891 us-gaap:ComputerEquipmentMember 2024-09-30 0001009891 us-gaap:ComputerEquipmentMember 2023-12-31 0001009891 srt:MinimumMember us-gaap:ComputerEquipmentMember 2024-09-30 0001009891 srt:MaximumMember us-gaap:ComputerEquipmentMember 2024-09-30 0001009891 srt:MinimumMember 2024-09-30 0001009891 srt:MaximumMember 2024-09-30 0001009891 2023-01-01 2023-12-31 0001009891 airi:CurrentCreditFacilityMember airi:WebsterBankMember 2024-01-01 2024-09-30 0001009891 us-gaap:RevolvingCreditFacilityMember airi:WebsterBankMember 2019-12-31 0001009891 us-gaap:LineOfCreditMember airi:WebsterBankMember 2019-12-31 2019-12-31 0001009891 airi:CurrentCreditFacilityMember 2024-07-01 2024-09-30 0001009891 airi:CurrentCreditFacilityMember 2023-07-01 2023-09-30 0001009891 airi:CurrentCreditFacilityMember 2024-01-01 2024-09-30 0001009891 airi:CurrentCreditFacilityMember 2023-01-01 2023-09-30 0001009891 srt:MaximumMember 2024-01-01 2024-09-30 0001009891 srt:MinimumMember 2024-01-01 2024-09-30 0001009891 airi:CurrentCreditFacilityMember 2023-08-04 0001009891 airi:CurrentCreditFacilityMember 2023-08-04 2023-08-04 0001009891 airi:CurrentCreditFacilityMember 2024-03-31 0001009891 airi:CurrentCreditFacilityMember 2024-06-30 0001009891 airi:CurrentCreditFacilityMember 2023-11-20 0001009891 airi:CurrentCreditFacilityMember 2023-11-20 2023-11-20 0001009891 2024-05-31 2024-05-31 0001009891 airi:CurrentCreditFacilityMember 2024-01-01 2024-06-30 0001009891 srt:ScenarioForecastMember airi:CurrentCreditFacilityMember 2024-01-01 2024-12-31 0001009891 srt:ScenarioForecastMember airi:CurrentCreditFacilityMember 2025-03-31 0001009891 srt:ScenarioForecastMember airi:CurrentCreditFacilityMember 2025-06-30 0001009891 srt:MinimumMember airi:CurrentCreditFacilityMember 2024-05-31 2024-05-31 0001009891 srt:MaximumMember airi:CurrentCreditFacilityMember 2024-05-31 2024-05-31 0001009891 airi:CurrentCreditFacilityMember 2024-05-31 2024-05-31 0001009891 us-gaap:RevolvingCreditFacilityMember 2024-09-30 0001009891 srt:MaximumMember airi:SolarCreditFacilityMember 2023-08-16 0001009891 airi:SolarCreditFacilityMember 2024-09-30 0001009891 airi:SolarCreditFacilityMember airi:ConnecticutGreenBankMember 2024-01-01 2024-09-30 0001009891 airi:SolarCreditFacilityMember airi:ConnecticutGreenBankMember 2024-09-30 0001009891 airi:SolarCreditFacilityMember 2024-10-01 2024-10-01 0001009891 airi:SolarCreditFacilityMember airi:ConnecticutGreenBankMember 2024-10-01 0001009891 srt:ScenarioForecastMember airi:SolarCreditFacilityMember airi:ConnecticutGreenBankMember 2025-07-01 2025-07-01 0001009891 airi:SolarCreditFacilityMember 2025-07-01 0001009891 airi:SolarCreditFacilityMember 2024-07-01 2024-09-30 0001009891 airi:SolarCreditFacilityMember 2023-07-01 2023-09-30 0001009891 airi:SolarCreditFacilityMember 2024-01-01 2024-09-30 0001009891 airi:SolarCreditFacilityMember 2023-01-01 2023-09-30 0001009891 airi:MichaelRobertTaglichBrothersIncMember 2024-01-01 2024-09-30 0001009891 airi:MichaelRobertTaglichBrothersIncMember 2024-09-30 0001009891 airi:MichaelRobertTaglichBrothersIncMember airi:AnnualIntrestRateSixPercentageMember 2024-09-30 0001009891 airi:MichaelRobertTaglichBrothersIncMember airi:AnnualRateSeveenPercentagMember 2024-09-30 0001009891 airi:MichaelRobertTaglichIncMember airi:AnnualInterestRateTwelvePercentageMember 2024-09-30 0001009891 airi:MichaelRobertTaglichBrothersIncMember airi:AnnualInterestRateTwelvePercentageMember 2024-09-30 0001009891 airi:MichaelRobertTaglichBrothersIncMember 2024-07-01 2024-09-30 0001009891 airi:MichaelRobertTaglichBrothersIncMember 2023-07-01 2023-09-30 0001009891 airi:MichaelRobertTaglichBrothersIncMember 2023-01-01 2023-09-30 0001009891 airi:ConvertibleSubordinatedNotesMember 2024-09-30 0001009891 airi:ConvertibleSubordinatedNotesMember 2024-01-01 2024-09-30 0001009891 us-gaap:RevolvingCreditFacilityMember 2023-12-31 0001009891 airi:LineOfCreditFacilityTermLoanMember 2024-09-30 0001009891 airi:LineOfCreditFacilityTermLoanMember 2023-12-31 0001009891 airi:SolarCreditFacilityMember 2023-12-31 0001009891 us-gaap:LoansPayableMember 2024-09-30 0001009891 airi:MichaelTaglichChairmanMember 2024-09-30 0001009891 airi:RobertTaglichDirectorMember 2024-09-30 0001009891 airi:TaglichBrothersIncMember 2024-09-30 0001009891 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001009891 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001009891 srt:ScenarioForecastMember 2024-10-01 2024-12-31 0001009891 airi:EquityIncentivePlan2022Member 2024-09-30 0001009891 srt:MinimumMember airi:EquityIncentivePlan2022Member 2024-09-30 0001009891 srt:MaximumMember airi:EquityIncentivePlan2022Member 2024-09-30 0001009891 airi:EquityIncentivePlan2022Member 2023-09-30 0001009891 srt:MinimumMember airi:EquityIncentivePlan2022Member 2023-09-30 0001009891 srt:MaximumMember airi:EquityIncentivePlan2022Member 2023-09-30 0001009891 airi:EmployeesAndMembersOfBoardOfDirectorsMember us-gaap:StockOptionMember 2024-07-01 2024-09-30 0001009891 airi:EmployeesAndMembersOfBoardOfDirectorsMember us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001009891 airi:EmployeesAndMembersOfBoardOfDirectorsMember us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001009891 airi:EmployeesAndMembersOfBoardOfDirectorsMember us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001009891 2024-08-13 2024-08-13 0001009891 2024-08-13 0001009891 2020-05-23 2020-05-23 0001009891 2020-05-23 0001009891 2023-06-02 2023-06-02 0001009891 2023-06-02 0001009891 airi:ManagementAndEmployeesMember 2023-06-02 2023-06-02 0001009891 airi:ManagementAndEmployeesMember 2023-06-02 0001009891 airi:NonVestedStockOptionMember 2024-01-01 2024-09-30 0001009891 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001009891 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001009891 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001009891 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001009891 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001009891 us-gaap:StockOptionMember airi:RangeOfExercisePriceOneMember 2024-09-30 0001009891 us-gaap:StockOptionMember airi:RangeOfExercisePriceOneMember 2024-01-01 2024-09-30 0001009891 us-gaap:StockOptionMember airi:RangeOfExercisePriceTwoMember 2023-12-31 0001009891 us-gaap:StockOptionMember airi:RangeOfExercisePriceTwoMember 2023-01-01 2023-12-31 0001009891 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001009891 2018-10-02 2018-10-02 0001009891 2021-07-08 2021-07-08 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure